Compare GSK plc (GSK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tesla, Inc. — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Tesla, Inc. trades at $327 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 12.8× GSK plc's market cap, and GSK plc pays a 3.57% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| GSK | TSLA | |
|---|---|---|
Market Cap | $102.60B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $489.88 |
52-Week Low | $38.22 | $298.16 |
Enterprise Value | $123.04B | $1.29T |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Tesla (TSLA) trades at $332.71, up 0.56% on the day, as the stock shows mixed signals with bearish technical indicators but recent positive earnings beats. The company faces declining profit margins (net income margin of 3.67% in 2025) despite steady revenue near $95B, while valuation ratios remain elevated with a P/E of 308. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model.
Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include competitive pressures and high valuation. Analyst consensus price target of $393.87 suggests 18% upside, though technical weakness and earnings volatility warrant caution. Investment opportunity hinges on Tesla's pivot beyond automotive into robotics and energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
